reason report
in-market product emerg pipelin bolster continu
bottom line morn announc
confer call updat model reiter
outperform rate regn stock increas price
target price target increas base
strong result steadili improv profit outlook
still account fraction compani pipelin
potenti forecast valuat expect antibodi
collabor sanofi gener sustain posit cash
earn contribut begin later morn
regeneron report result beat consensu top
bottom line total revenu consensu
estim pro forma ep
consensu estim number benefit
one-tim adjust sanofi collabor revenu
beat would modest ep
exclud adjust compani reiter financi
guidanc announc earli januari despit potenti
competit threat novarti eylea could emerg later
year believ growth new indic eylea
dupix asthma adolesc atop dermat ad us
launch new geographi libtayo cutan
squamou cell carcinoma cscc off-set risk
slow eylea sale new trial readout includ first proof-of-
concept studi regn new co-stimulatori bispecif
antibodi activin antibodi muscl disord could add
modest chang model pt given latest sale trend
growth outlook modestli rais revenu forecast
eylea sanofi collabor lower estim dupix
praluent forecast sanofi collabor turn cash flow
posit later result revenu forecast regeneron
increas remain recent
consensu consensu
estim oper margin higher
increas non-gaap ep forecast
ep forecast remain recent consensu
consensu base
chang estim chang peer compani
multipl price target increas reiter
outperform rate
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
previous cover highlight regeneron
confer call recap note link
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani come initi base portfolio fast-
follow second entrant rapidli grow biopharmaceut market first product eylea
continu surpris investor taken grown market intraocular
vegf vascular endotheli growth factor antibodi treatment eylea contribut
global sale trump categori pioneer roch lucenti well
cheaper altern compound bevacizumab remain posit eylea expect
continu grow lose market share emerg competitor
novarti seem like approv excit aspect
compani next wave innov antibodi notabl dupix approv
adult atop dermat asthma like receiv label expans multipl allerg
diseas indic expect dupix dupilumab gener revenu
signific upsid indic longer term regeneron wholli own
antibodi could contribut meaning revenu earn growth
period current compani invest mode result earn cash flow
convers revenu lag peer industri anticip cash flow true
earn improv period profit antibodi collabor
sanofi begin accumul
comfort top-lin upsid even net one-tim item total revenu
consensu estim total
revenu boost one-tim payment regeneron partner sanofi
regeneron report global eylea sale consensu line
estim us sale eylea consensu
estim ex-u eylea sale consensu
slightli estim dupix sale consensu
estim praluent sale consensu line
forecast total collabor revenu regeneron partnership sanofi bayer
teva mp quarter consensu
estim primarili driven cumul catch-up adjust connect
amend io discoveri agreement sanofi exclud one-tim adjust total
collabor revenu would vs consensu vs
expens side regeneron report total non-gaap oper expens
consensu estim higher-than-expect
oper expens mainli driven expens vs consensu
line oper margin ex-item narrow
regeneron also report higher tax rate compar consensu
forecast compani transit durabl normal tax basi
forma ep result beat consensu forecast
note ep would exclud catch-up adjust repres
prior guidanc reiter regeneron re-affirmed guidanc first announc last
month compani guid sanofi reimburs regeneron commercialization-rel
expens line initi estim consensu avail
non-gaap unreimburs guid higher consensu
consist initi estim grow
non-gaap sg guidanc line consensu
initi estim grow regeneron also expect
effect tax rate rang lower consensu line
initi forecast guidanc capit expenditur
label expans in-market product emerg candid progress
regeneron slew new indic market open compani expect
label expans eylea diabet retinopathi dr pdufa date may although
manag caution opportun new indic may immedi becom
growth driver due patient physician educ requir drive treatment adopt
popul despit complet respons letter sbla eylea pre-fil
syring manag believ still track potenti launch syring
formul upon expect submiss supplementari data bla
dupix compani expect three regulatori mileston includ fda
approv adolesc atop dermat ad pdufa date march ema approv
asthma accept sbla chronic rhinosinus nasal polyposi
phase result dupix ad patient age year phase result
asthma monotherapi combin dupix expect
read year immuno-oncolog i/o franchis regeneron plan initi studi
libtayo cutan squamou cell carcinoma cscc adjuv neoadjuv set
initi potenti pivot trial bispecif non-hodgkin
lymphoma manag comment feel identifi right dose rang
follicular lymphoma diffus larg b-cell lymphoma
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo nv
azn earn multipl ep appli current
ep estim give valu use high growth revenu multipl
similar compani nvo consensu sale
appli revenu estim give valu lastli dcf
valuat given wacc termin cash flow growth rate give present valu
averag three method current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand compani cholesterol treatment praluent lastli compani convert rel
littl revenu cash flow today histori return cash investor
ultim may undermin valu stock investor willing continu
sale
collabor
share count period dilut mm
guidanc
tax non-gaap pre-tax incom
sanofi reimburs regeneron
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
libtayo nsclc
eylea dr w/o dme libtayo basal
brand
type event
event trial detail
fda approv adolesc patient
fda approv cv outcom data
fda re-submiss pre-fil syring
phase result follow safeti
year age
svb leerink llc research compani file
date known
up/down
leerink view
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
svb leerink regeneron select balanc sheet cash-flow item
million
cash equival
properti plant equip net
total liabil sharehold equiti
net incom loss option expens forma
chang asset liabil
chang market secur
issuanc stock/ purchas treasuri stock
proce long-term borrow
repay long-term borrow
net chang cash/equival
begin period
end period
 increas work capit
 acquisit licens invest
oper
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap growth biotech ep multipl
ep nvo nv azn
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
